A model of mild hypoglycemia

References

• van Dieren S, Beulens JW, van der Schouw YT, et al. The global burden of diabetes and its complications: an emerging pandemic. Eur J Cardiovasc Prev Rehabil 2010;17(Suppl 1):S3-8
   PubMed Web of Science ®Google Scholar
• Dardano A, Penno G, Del Prato S, Miccoli R. Optimal therapy of type 2 diabetes: a controversial challenge. Aging 2014;6:187-207
   PubMedGoogle Scholar
• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-86
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes 2011. Diabetes Care 2011;34(Suppl 1):11-61
   PubMed Web of Science ®Google Scholar
• Davis S, Alonso MD. Hypoglycemia as a barrier to glycemic control. J Diabetes Complications 2004;18:60-8
   PubMed Web of Science ®Google Scholar
• Cryer PE. Hypoglycemia: still the limiting factor in the glycemic management of diabetes. Endocr Pract 2008;14:750-6
   PubMedGoogle Scholar
• Marrett E, Radican L, Davies MJ, Zhang Q. Assessment of severity and frequency of self-reported hypoglycemia on quality of life in patients with type 2 diabetes treated with oral antihyperglycemic agents: a survey study. BMC Res Notes 2011;4:251
   PubMedGoogle Scholar
• Cryer PE. Symptoms of hypoglycemia, thresholds for their occurrence, and hypoglycemia unawareness. Endocrinol Metabol Clin N Am 1999;28:495-500, v-vi
   PubMed Web of Science ®Google Scholar
• Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 2013;36:1384-95
   PubMed Web of Science ®Google Scholar
• UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007;50:1140-7
   PubMed Web of Science ®Google Scholar
• Bodmer M, Meier C, Krahenbuhl S, et al. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case–control analysis. Diabetes Care 2008;31:2086-91
   PubMed Web of Science ®Google Scholar
• Curkendall SM, Zhang B, Oh KS, et al. Incidence and cost of hypoglycemia among patients with type 2 diabetes in the United States: analysis of a health insurance database. J Clin Outcomes Manage 2011;18:455-62
   Google Scholar
• Johnston SS, Conner C, Aagren M, et al. Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes. Diabetes Care 2011;34:1164-70
   PubMed Web of Science ®Google Scholar
• Khalid JM, Raluy-Callado M, Curtis BH, et al. Rates and risk of hospitalisation among patients with type 2 diabetes: retrospective cohort study using the UK General Practice Research Database linked to English Hospital Episode Statistics. Int J Clin Pract 2014;68:40-8
   PubMed Web of Science ®Google Scholar
• Tahrani A, Barnett AH, Brod M, et al. GAPP2™: Global Survey Finds Three Quarters of Patients Experience Hypoglycaemia on Insulin Analogue Causing Dose Irregularities and Increased Blood Glucose Monitoring. European Association for the Study of Diabetes (EASD), October 2012
   Google Scholar
• Brod M, Christensen T, Thomsen TL, Bushnell DM. The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health 2011;14:665-71
   PubMed Web of Science ®Google Scholar
• Desouza CV, Bolli GB, Fonseca V. Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care 2010;33:1389-94
   PubMed Web of Science ®Google Scholar
• Zoungas S, Patel A, Chalmers J, et al. ADVANCE supplement to: severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010;363:1410-18
   PubMed Web of Science ®Google Scholar
• Taylor JR. Diabetes medications in renal insufficiency. 2010. Available at: http://www.healio.com/endocrinology/diabetes/news/print/endocrine-today/%7Bc7db0ce2-1d41-4d48-aecc-86c330a8d67e%7D/diabetes-medications-in-renal-insufficiency [Last accessed 14 February 2014]
   Google Scholar
• Bloomfield HE, Greer N, Newman D, et al. Predictors and Consequences of Severe Hypoglycemia in Adults with Diabetes – A Systematic Review of the Evidence. VA-ESP Project #09-009. 2012. Available at: http://www.hsrd.research.va.gov/publications/esp/hypoglycemia-2012.pdf [Last accessed 14 August 2014]
   Google Scholar
• Pontiroli AE, Miele L, Morabito A. Metabolic control and risk of hypoglycaemia during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis. Diabetes Obes Metabol 2012;14:433-46
   PubMed Web of Science ®Google Scholar
• Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-39
   PubMed Web of Science ®Google Scholar
• Miller CD, Phillips LS, Ziemer DC, et al. Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med 2001;161:1653-9
   PubMed Web of Science ®Google Scholar
• Bennett WL, Wilson LM, Bolen S, et al. Oral Diabetes Medications for Adults With Type 2 Diabetes: An Update. Comparative Effectiveness Review No. 27. (Prepared by Johns Hopkins University Evidence-based Practice Center under Contract No. 290-02-0018.) AHRQ Publication No. 11-EHC038-EF 2011. Available at: http://effectivehealthcare.ahrq.gov/ehc/products/155/644/type-2-diabetes-medications-report-130911.pdf [Last accessed 11 December 2013]
   Google Scholar
• Simeone JC, Quilliam BJ. Predictors of emergency department and outpatient visits for hypoglycemia in type 2 diabetes: an analysis of a large US administrative claims database. Ann Pharmacother 2012;46:157-68
   PubMed Web of Science ®Google Scholar
• Vickova V, Cornelius V, Kasliwal R, et al. Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide. Drug Saf 2009;32:409-18
   PubMed Web of Science ®Google Scholar
• Tschope D, Bramlage P, Binz C, et al. Incidence and predictors of hypoglycaemia in type 2 diabetes – an analysis of the prospective DiaRegis registry. BMC Endocr Disord 2012;12:23
   PubMed Web of Science ®Google Scholar
• Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43
   PubMed Web of Science ®Google Scholar
• Fabunmi R, Nielsen LL, Quimbo R, et al. Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine. Curr Med Res Opin 2009;25:777-86
   PubMed Web of Science ®Google Scholar
• Fonseca V, Gill J, Zhou R, Leahy J. An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia. Diabetes Obes Metabol 2011;13:814-22
   PubMed Web of Science ®Google Scholar
• Goudswaard AN, Furlong NJ, Valk GD, Stolk RP, Rutten GEHM. Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2004, Issue 4. Art. No.: CD003418. doi: 10.1002/14651858.CD003418.pub2
   Google Scholar
• Hemmingsen B, Christensen LL, Wetterslev J, et al. Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses. BMJ 2012;344:e1771
   PubMed Web of Science ®Google Scholar
• Schernthaner G, Grimaldi A, Di Mario U, et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Investig 2004;34:535-42
   PubMed Web of Science ®Google Scholar
• Tschope D, Bramlage P, Binz C, et al. Antidiabetic pharmacotherapy and anamnestic hypoglycemia in a large cohort of type 2 diabetic patients – an analysis of the DiaRegis registry. Cardiovasc Diabetol 2011;10:66. doi:10.1186/1475-2840-10-66
   PubMed Web of Science ®Google Scholar
• Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628-35
   PubMed Web of Science ®Google Scholar
• DeFronzo R, Ratner R, Han J, et al. Effects of exenatide (synthetic exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes (Abstract). American Diabetes Association 64th Annual Scientific Sessions. Orlando, Florida, 2004
   Google Scholar
• White JR. Dipeptidyl peptidase-IV inhibitors: pharmacological profile and clinical use. Clin Diabetes 2008;26:53-7
   Google Scholar
• Bydureon (exenatide) label. 2012. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022200Orig1s000lbledt.pdf [Last accessed 12 December 2013]
   Google Scholar
• Byetta (exenatide) label. 2009. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021773s9s11s18s22s25lbl.pdf [Last accessed 12 December 2013]
   Google Scholar
• Victoza (liraglutide) label. 2010. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022341lbl.pdf [Last accessed 12 December 2013]
   Google Scholar
• Januvia (sitagliptin) label. 2012. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021995s019lbl.pdf [Last accessed 12 December 2013]
   Google Scholar
• Donnelly LA, Morris AD, Frier BM, et al. Frequency and predictors of hypoglycaemia in type 1 and insulin-treated type 2 diabetes: a population-based study. Diabet Med 2005;22:749-55
   PubMed Web of Science ®Google Scholar
• Mullins P, Sharplin P, Yki-Jarvinen H, et al. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus. Clin Therapeut 2007;29:1607-19
   PubMed Web of Science ®Google Scholar
• Nielsen RZ, Davidsen CK. Describing Hypoglycemic Events Using Extensions of the Cox Model. Kongens Lyngby, Denmark: Department of Informatics and Mathematical Modelling, Technical University of Denmark, 2011. Thesis available at: http://etd.dtu.dk/thesis/274780/ep11_05 [Last accessed 14 August 2014]
   Google Scholar
• Vespasiani G, Freemantle N, Balkau BJ, et al. Risk factors for symptomatic hypoglycaemia in people with type 2 diabetes mellitus initiated on insulin therapy: evidence from the CREDIT study. Presentation number 577. 46th Annual Meeting of the European Association for the Study of Diabetes (EASD) Stockholm, Sweden, 2010
   Google Scholar
• Wright AD, Cull CA, Macleod KM, et al. Hypoglycemia in type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73. J Diabetes Complications 2006;20:395-401
   PubMed Web of Science ®Google Scholar
• Karl DM, Gill J, Zhou R, Riddle MC. Clinical predictors of risk of hypoglycaemia during addition and titration of insulin glargine for type 2 diabetes mellitus. Diabetes Obes Metabol 2013;15:622-8
   PubMed Web of Science ®Google Scholar
• Miller ME, Bonds DE, Gerstein HC, et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ 2010;340:b5444
   PubMed Web of Science ®Google Scholar
• Moen MF, Zhan M, Hsu VD, et al. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol 2009;4:1121-7
   PubMed Web of Science ®Google Scholar
• Shorr RI, Ray WA, Daugherty JR, Griffin MR. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med 1997;157:1681-6
   Google Scholar
• Foos V, Varol N, Curtis BH, et al. Economic impact of severe and non-severe hypoglycemia in patients with Type 1 and Type 2 diabetes in the United States. J Med Econ. Epub doi:10.3111/13696998.2015.1006730
   Google Scholar
• Garg SK, Aurand LA, Rimler MS, Dailey GE. Diabetes duration and the efficacy and safety of insulin glargine versus comparator treatment in patients with type 2 diabetes mellitus. Endocr Pract 2014;20:120-8
   Google Scholar
• Seufert J, Brath H, Pscherer S, et al. Composite efficacy parameters and predictors of hypoglycaemia in basal-plus insulin therapy-a combined analysis of 713 type 2 diabetic patients. Diabetes Obes Metab 2014;16:248-5
   Google Scholar
• Eddy DM, Schlessinger L. Validation of the Archimedes diabetes model. Diabetes Care 2003;26:3102-10
   PubMed Web of Science ®Google Scholar
• Aschner P, Chan J, Owens DR, et al. Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial. Lancet 2012;379:2262-9
   PubMed Web of Science ®Google Scholar
• HOE Study Investigators Group. Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with oral treatment in Type 2 diabetic patients. Diabet Med 2003;20:545-51
   PubMed Web of Science ®Google Scholar
• Hajos TR, Pouwer F, de Grooth R, et al. Initiation of insulin glargine in patients with type 2 diabetes in suboptimal glycaemic control positively impacts health-related quality of life. A prospective cohort study in primary care. Diabet Med 2011;28:1096-102
   PubMed Web of Science ®Google Scholar
• Pan CY, Sinnassamy P, Chung KD, et al. Insulin glargine versus NPH insulin therapy in Asian type 2 diabetes patients. Diabetes Res Clin Pract 2007;76:111-18
   PubMed Web of Science ®Google Scholar
• Strojek K, Bebakar WM, Khutsoane DT, et al. Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT. Curr Med Res Opin 2009;25:2887-94
   PubMed Web of Science ®Google Scholar
• Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006;49:442-51
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. 2011. Available at: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf [Last accessed 12 December 2013]
   Google Scholar
• Gangji AS, Cukierman T, Gerstein HC, et al. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care 2007;30:389-94
   PubMed Web of Science ®Google Scholar